Does having the CYP2C19*2 gene variant protect against cyclophosphamide side effects in lupus nephritis?
Cyclophosphamide is a strong immunosuppressant used for lupus nephritis, but it can cause serious side effects. Some people have a gene variant called CYP2C19*2 that may affect how their body processes the drug. Research suggests this variant might lower the risk of toxicity, making treatment safer for those who carry it.
What the research says
A meta-analysis of five studies found that lupus nephritis patients with the CYP2C19*2 genetic variant had a significantly lower risk of cyclophosphamide-induced toxicity compared to those without the variant 2. The odds ratio was 0.28, meaning the variant was associated with about a 72% reduction in the odds of toxicity 2. However, the analysis noted potential publication bias and some concerns about study quality, so the evidence is not definitive 2. Other sources on lupus nephritis discuss different treatments and genetic factors, but do not directly address CYP2C19*2 1345678.
What to ask your doctor
- Should I be tested for the CYP2C19*2 gene variant before starting cyclophosphamide?
- If I have the variant, does that mean I can expect fewer side effects from cyclophosphamide?
- Are there other genetic tests that might help predict my risk of side effects from lupus nephritis treatments?
- How does the protective effect of this variant compare to other ways to reduce cyclophosphamide toxicity?
This question is drawn from common patient questions about this topic and answered using cited medical research. We do not provide individualized advice.